MedTrace Logo

Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00004915 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-06

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen.

PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.

Conditions

Interventions

DRUG

raloxifene

Sponsors & Collaborators

Principal Investigators

  • Phillip Y. Roland, MD · Florida Gynecologic Oncology - Fort Myers

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-11-30
Primary Completion
2000-02-29
Completion
2000-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004915 on ClinicalTrials.gov